




Point-of-care Blood Clot Analysis Platform

Revolutionizing Testing With Minimal Blood And
Maximum Insights


Levisonics Inc.
www.levisonics.com



1.6 Billion People Worldwide Are Affected By Conditions Impacting Bleeding Or Clotting




There Is A Big Need for Easy, Safe, And Comprehensive Blood Coagulation Testing



- Blood coagulation is a complex but important process in the body.
- Clotting involves multiple factors and proteins.
- Diagnosing bleeding or clotting issues is currently very complicated.
- Doctors require a combination of multiple different tests for accurate diagnosis.
- These tests need large amount of blood sample.
- Multiple tests often mean multiple blood draws.
- Existing tests don't serve vulnerable patients like children.




Our Solution: Minimally Invasive Test With Comprehensive Results



- 6 microliters of blood needed per test
- Noncontact test avoids sample contamination
- Outputs 8 comprehensive clotting parameters
- Fully functional minimal viable prototypes
- Convenient, portable, countertop device
- Easy to use and faster test results


Our Innovative Technology



- Our patented technology uses sound waves to levitate and analyze blood drops.
- Tracks changes in location and shape of the drop during a test.
- Measures mechanical and optical properties of the blood, like current standard tests.
- Need less blood (only 6 microliters per test) easily collected from finger prick.
- Outputs quantitatively and qualitatively superior test results compared to the status quo and provide a more holistic view of the patient's clot profile.



Our Solution Offers Value To All Stakeholders



Patients

- Reduce Adverse Events
- Less discomfort



Physicians

- Empowered with 2x actionable data
- Better diagnosis
- Point of care convenience




Payers

- Avoid multiple tests
- Reduce repeat visits
- Reduce care costs



Our Unfair Competitive Advantage: We Output More Data With Less Blood



Our Business Model



Devices

- Sale or Lease
- Price: \$30k - \$45k
- Profit Margin: 60%




Consumables

- Recurring sales
- Price: \$100
- Profit Margin: 80%



Maintenance Contracts

- Labor and parts
- Profit Margin: 60%



Regulatory Strategy

Description:

Drop-of-blood device for comprehensive coagulation analysis via acoustic tweezing

Intended Use:


Monitoring of blood coagulation

Patient Population:

Pediatric and adult patients with hematological disorders

Care Setting:

Professional Point of Care – Exam Room/Doctor’s office, Hospital Lab, Special Coagulation Lab, Research Lab, Operating Room




USA Regulatory Classification	
Medical Device	Yes
FDA Center	Center for Devices & Radiological Health
US Classification	Class II
Submission Type	510k – Introduction of new technology May need De Novo Classification for Home Use
FDA Review Panel	Hematology
Code of Federal Regulation Description	Non-Significant Risk Device
FDA Product Code	JPA or QFR
FDA Product Code Description	JPA: System, Multipurpose For In Vitro Coagulation Control QFR: Coagulation system for the measurement of whole blood viscoelastic properties
Pre-Market Clinical Study Required	No

United States Market Analysis

> 244 M
Tests Per Year

65 M
Patients

4 M
Children



Available Market

Lab (\$1.1B; Hospital \$420M;
Home \$50M); CAGR 7.5%

Addressable Market

Outpatient, Home and
33% Inpatient

Initial Target Market

Pediatric Segment
11.9 M tests @ \$10.50/test

Gaps in current market: Pediatrics & Outpatient Clinics



Go To Market Strategy

1. Pediatrics

- Children's Hospitals (324)
- Hemophilia Treatment Centers (147)
- Pediatric Wards in Hospitals (1,418)
- PICUs (349)



2. Adults

- Hospitals (~5,100)
- Clinics (~34,800)
- Infusion Centers (~3,600)
- Military Use

3. Biomedical Research

- Drug discovery
- Veterinary
- Biofluid Analysis



4. Near Patient

- At Home Therapy Monitoring
- Retail Clinics (~2,700)
- Mobile care units

Direct Sales

Sales via Strategic Partnerships



Traction

10+ years

Research And Development

6 TRL

With Phase I Product

4 Patents

Exclusive License + In House

6 MVPs

For Pilot Clinical Studies

6+

Peer Reviewed
Publications

120+

Customer Discovery Interviews

\$6.3 Million

Non-dilutive Grant Funding

510k pathway

3 Predicates Identified



Our Team



Nithya Kasireddy, Ph.D.
Chief Executive Officer
Board of Director



Damir Khismatullin, Ph.D.
Co-founder
Board of Director



Glynn Holt, Ph.D.
Co-founder
Board of Director



Manik Dautta, Ph.D.
Lead Engineer




Our Strengths

- Decades of experience in acoustics and biomedical research
- Strong scientific and technical expertise.
- Multiple collaborations with potential customers
- Supporting team of consultants and advisors


Collaboration and Support



Milestones




Multiple Options For Acquisition



Our Ask

Seeking \$2 Million Seed Round To Complete MMP
Validation Testing And FDA Submission

Use of Funds



Additional Ways To Support Us



Investor
Introductions/
Referrals



Introductions with
Hospital Networks



Introductions To
Pediatric Care
Facilities



Introductions to
Potential Strategic
Partners



Introductions to
Industry Experts



Mentorship/
Advisory Support





Point-of-care Blood Clot Analysis Platform

Revolutionizing Testing With Minimal Blood And
Maximum Insights

Contact Us

Nithya Kasireddy

CEO, Levisonics Inc.

nkasireddy@levisonics.com

www.levisonics.com

